Page 606 - Read Online

Page 26 of 26 Ralph et al. J Cancer Metastasis Treat 2018;4:49 I http://dx.doi.org/10.20517/2394-4722.2018.42

signalling. Sci Rep 2018;8:6271.
160. Irie T, Tsujii M, Tsuji S, Yoshio T, Ishii S, Shinzaki S, Egawa S, Kakiuchi Y, Nishida T, Yasumaru M, Iijima H, Murata H, Takehara T,
Kawano S, Hayashi N. Synergistic antitumor effects of celecoxib with 5-fluorouracil depend on IFN-gamma. Int J Cancer 2007;121:878-83.
161. Zhao S, Cai J, Bian H, Gui L, Zhao F. Synergistic inhibition effect of tumor growth by using celecoxib in combination with oxaliplatin.
Cancer Invest 2009;27:636-40.
162. Sadhu SS, Wang S, Averineni RK, Seefeldt T, Yang Y, Guan X. In-vitro and in-vivo inhibition of melanoma growth and metastasis by the
drug combination of celecoxib and dacarbazine. Melanoma Res 2016;26:572-9.
163. van Wijngaarden J, van Beek E, van Rossum G, van der Bent C, Hoekman K, van der Pluijm G, van der Pol MA, Broxterman HJ, van
Hinsbergh VW, Löwik CW. Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kappaB-mediated increase
of intracellular doxorubicin accumulation. Eur J Cancer 2007;43:433-42.
164. Angelini A, Iezzi M, Di Febbo C, Di Ilio C, Cuccurullo F, Porreca E. Reversal of P-glycoprotein-mediated multidrug resistance in human
sarcoma MES-SA/Dx-5 cells by nonsteroidal anti-inflammatory drugs. Oncol Rep 2008;20:731-5.
165. Fantappiè O, Solazzo M, Lasagna N, Platini F, Tessitore L, Mazzanti R. P-glycoprotein mediates celecoxib-induced apoptosis in multiple
drug-resistant cell lines. Cancer Res 2007;67:4915-23.
166. Hiľovská L, Jendželovský R, Fedoročko P. Potency of non-steroidal anti-inflammatory drugs in chemotherapy. Mol Clin Oncol 2015;3:3-
12.
167. Moreno-Sánchez R, Bravo C, Vásquez C, Ayala G, Silveira LH, Martínez-Lavín M. Inhibition and uncoupling of oxidative phosphorylation
by nonsteroidal anti-inflammatory drugs: study in mitochondria, submitochondrial particles, cells, and whole heart. Biochem Pharmacol
1999;57:743-52.
168. Jin CH, Wang AH, Chen JM, Li RX, Liu XM, Wang GP, Xing LQ. Observation of curative efficacy and prognosis following combination
chemotherapy with celecoxib in the treatment of advanced colorectal cancer. J Int Med Res 2011;39:2129-40.
169. Debucquoy A, Roels S, Goethals L, Libbrecht L, Van Cutsem E, Geboes K, Penninckx F, D’Hoore A, McBride WH, Haustermans
K. Double blind randomized phase II study with radiation+5-fluorouracil+/-celecoxib for resectable rectal cancer. Radiother Oncol
2009;93:273-8.
170. Lin EH, Curley SA, Crane CC, Feig B, Skibber J, Delcos M, Vadhan SR, Morris J, Ayers GD, Ross A, Brown T, Rodriguez-Bigas MA,
Janjan N. Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common
mediator in pain, toxicities and survival? Am J Clin Oncol 2006;29:232-9.
171. Lin EH, Kim EY, Wang L, Fong C, Shankaran V, Wu X. ADAPT therapy vs capecitabine bevacizumab in stage IV colorectal cancer: pooled
10-year survival experience and a phase II study update. Available from: http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.
e15046. [Last accessed on 12 Sep 2018]
172. Lin EH, Patel SA, Chou J, Kim EY, Shankaran V, Coveler AL, Harris WP, Park JO, Fichera A, Mann GN, Chiorean EG, Pritchard CC,
Sinanan M, Upton M, Storer B, Yeung RS, Li L. A phase II trial of maintenance ADAPT therapy targeting colon cancer stem cells in
patients with metastatic colorectal cancer. Available from: http://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.tps3650. [Last accessed
on 12 Sep 2018]
173. Coombes RC, Tovey H, Kilburn L, Mansi J, Palmieri C, Bartlett J, Hicks J, Makris A, Evans A, Loibl S, Denkert C, Murray E, Grieve R,
Coleman R, Schmidt M, Klare P, Rezai M, Rautenberg B, Klutinus N, Rhein U, Mousa K, Ricardo-Vitorino S, von Minckwitz G, Bliss J.
A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT – Randomised
EuropeAn celecoxib trial). Available from: http://cancerres.aacrjournals.org/content/78/4_Supplement/GS3-03. [Last accessed on 12 Sep
2018]
174. Zhou YY, Hu ZG, Zeng FJ, Han J. Clinical Profile of cyclooxygenase-2 inhibitors in treating non-small cell lung cancer: a meta-analysis of
nine randomized clinical trials. PLoS One 2016;11:e0151939.
175. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AWS, Russell JM, Parker CC, Rentsch CA, Wallace
J, Barber J, Lydon A, Parmar MKB. Celecoxib with or without zoledronic acid for hormone-naïve prostate cancer: survival results from
STAMPEDE (NCT00268476). Clin Adv Hematol Oncol 2016;14:11-3.